Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab - Scorecard - MDSpire

Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

  • By

  • Seray Saray

  • Berke Engin

  • Ahmet Kadıoğlu

  • Mustafa Akın

  • Hüseyin Kanmaz

  • Yakup İriağaç

  • February 26, 2026

  • 0 min

Share

Clinical Scorecard: Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingOncology clinics, specifically Balıkesir Atatürk City Hospital (single-center study).

Key Highlights

  • highlight_3

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular follow-up for progression-free survival (PFS) and overall survival (OS) every 3 months.
      • Monitor for oligoprogression during treatment using imaging studies.

      Risks

        Patient & Prescribing Data

        Patients received platinum-based chemotherapy (cisplatin or carboplatin) before nivolumab initiation, typically within 3-6 months prior.

        Clinical Best Practices

        • best_practice_2

        References

        Original Source(s)

        Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

        • by Seray Saray, Berke Engin, Ahmet Kadıoğlu, Mustafa Akın, Hüseyin Kanmaz, Yakup İriağaç

        • February 26, 2026

        Related Content

        Quality over quantity: biopsy-anchored CT radiogenomics models outperform all-lesion training in a multi-tumour cohort despite a smaller sample size

        Targeted therapy combined with local consolidative surgery for oligometastatic stage IVA lung adenocarcinoma with CCDC6-RET fusion: a case report

        Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer